ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

This publication has 12 references indexed in Scilit:

• Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies
  Journal of Clinical Oncology, 2001
• Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225
  British Journal of Dermatology, 2001
• Pharmacokinetics and Tolerability of the Orally Active Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Healthy Volunteers
  Clinical Pharmacokinetics, 2001
• Reduced growth rate accompanied by aberrant epidermal growth factor signaling in drug resistant human breast cancer cells
  Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2000
• Kinase Inhibitors in Cancer Therapy
  Drugs, 2000
• Epidermal growth factor-related peptides and their receptors in human malignancies
  Published by Elsevier ,2000
• Differential expression of epidermal growth factor receptor in human head and neck cancers
  Head & Neck, 1998
• ZD1839, AN EPIDERMAL GROWTH FACTOR TYROSINE KINASE INHIBITOR SELECTED FOR CLINICAL DEVELOPMENT
  Journal of Immunotherapy, 1997
• Antiapoptotic Signalling by the Insulin-Like Growth Factor I Receptor, Phosphatidylinositol 3-Kinase, and Akt
  Molecular and Cellular Biology, 1997
• Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
  Investigational New Drugs, 1992